

Gridley Adam  
Form 4  
October 03, 2018

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Gridley Adam

(Last) (First) (Middle)

C/O HISTOGENICS CORPORATION, 830 WINTER STREET, 3RD FLOOR

(Street)

WALTHAM, MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
HISTOGENICS CORP [HSGX]

3. Date of Earliest Transaction  
(Month/Day/Year)  
10/01/2018

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
President and CEO

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)		
				(A) or (D)	Code	V	Amount	(D)	Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transaction	5. Number of Derivative Securities	6. Date Exercisable and Expiration Date	7. Title and Am Underlying Sec
------------------------	---------------	--------------------------------------	-------------------------------	----------------	------------------------------------	---	--------------------------------

Edgar Filing: Gridley Adam - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security	any (Month/Day/Year)	Code (Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/Year)		(Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	A N S
Employee Stock Option (Right to Buy)	\$ 7.99	10/01/2018	<u>D</u> <sup>(1)</sup>			197,435		<u>(2)</u>	04/29/2024	Common Stock	1
Employee Stock Option (Right to Buy)	\$ 0.568	10/01/2018	<u>A</u> <sup>(1)</sup>			197,435		<u>(2)</u>	04/29/2024	Common Stock	1
Employee Stock Option (Right to Buy)	\$ 8.97	10/01/2018	<u>D</u> <sup>(1)</sup>			38,220		<u>(3)</u>	07/16/2024	Common Stock	3
Employee Stock Option (Right to Buy)	\$ 0.568	10/01/2018	<u>A</u> <sup>(1)</sup>			38,220		<u>(3)</u>	07/16/2024	Common Stock	3
Employee Stock Option (Right to Buy)	\$ 9.96	10/01/2018	<u>D</u> <sup>(1)</sup>			104,000		<u>(4)</u>	02/26/2025	Common Stock	1
Employee Stock Option (Right to Buy)	\$ 0.568	10/01/2018	<u>A</u> <sup>(1)</sup>			104,000		<u>(4)</u>	02/26/2025	Common Stock	1
Employee Stock Option (Right to Buy)	\$ 1.58	10/01/2018	<u>D</u> <sup>(1)</sup>			175,000		<u>(5)</u>	12/16/2026	Common Stock	1
Employee Stock Option (Right to Buy)	\$ 0.568	10/01/2018	<u>A</u> <sup>(1)</sup>			175,000		<u>(5)</u>	12/16/2026	Common Stock	1

Employee Stock Option (Right to Buy)	\$ 1.72	10/01/2018	D <sup>(1)</sup>	175,000	(6)	02/14/2027	Common Stock	1
Employee Stock Option (Right to Buy)	\$ 0.568	10/01/2018	A <sup>(1)</sup>	175,000	(6)	02/14/2027	Common Stock	1
Employee Stock Option (Right to Buy)	\$ 2.63	10/01/2018	D <sup>(1)</sup>	300,000	(7)	02/15/2028	Common Stock	3
Employee Stock Option (Right to Buy)	\$ 0.568	10/01/2018	A <sup>(1)</sup>	300,000	(7)	02/15/2028	Common Stock	3
Employee Stock Option (Right to Buy)	\$ 9.96	10/01/2018	D <sup>(8)</sup>	60,000	(9)	02/26/2025	Common Stock	0

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Gridley Adam C/O HISTOGENICS CORPORATION 830 WINTER STREET, 3RD FLOOR WALTHAM, MA 02451	X		President and CEO	

## Signatures

/s/ Adam  
Gridley

10/02/2018

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on October 1, 2018. Pursuant to the Option Repricing, the exercise price of each "Relevant Option" (any stock option awarded by the Issuer under its 2012 Equity Incentive Plan or 2013 Equity Incentive Plan with an exercise price greater than \$ 0.75628 per share held by current service

## Edgar Filing: Gridley Adam - Form 4

providers other than the non-employee members of the Issuer's board of directors) has been amended to reduce such exercise price to \$0.568, which was the closing price of a share of the Issuer's common stock reported on The Nasdaq Capital Market on October 1, 2018. There have been no other changes to the terms of the Relevant Options.

- (2) The stock option was originally granted to the Reporting Person on April 30, 2014 and is vested with respect to all of the shares underlying the option.
- (3) The stock option was originally granted to the Reporting Person on July 17, 2014 and is vested with respect to all of the shares underlying the option.

The stock option was originally granted to the Reporting Person on February 26, 2015. This option vests over four (4) years of service following February 26, 2016, with twenty-five percent (25%) vesting upon completion of one (1) year of continuous service and in thirty-six (36) equal monthly installments thereafter.
- (5) The stock option was originally granted to the Reporting Person on December 16, 2016. This option vests over four (4) years of service to the Issuer following February 26, 2016, with twenty-five percent (25%) vesting upon completion of one (1) year of continuous service to the Issuer following such date and the balance vesting in thirty-six (36) equal monthly installments thereafter.
- (6) The stock option was originally granted to the Reporting Person on February 14, 2017. This option vests over four (4) years of service to the Issuer following February 14, 2017, with twenty-five percent (25%) vesting upon completion of one (1) year of continuous service to the Issuer following such date and the balance vesting in thirty-six (36) equal monthly installments thereafter.
- (7) The stock option was originally granted to the Reporting Person on February 16, 2018. This option vests over four (4) years of service to the Issuer following February 16, 2018, with twenty-five percent (25%) vesting upon completion of one (1) year of continuous service to the Issuer following such date and the balance vesting in thirty-six (36) equal monthly installments thereafter.
- (8) This transaction reflects the cancellation for no consideration of certain outstanding stock options to purchase common stock of the Issuer that were previously granted to the Reporting Person (the "Cancelled Options").
- (9) The Cancelled Option was originally granted to the Reporting Person on February 26, 2015 and was to vest in full if the Issuer's Common Stock price reached \$19.92 per shares or above for any consecutive sixty (60) day period within four (4) years of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.